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Myeloid Sarcoma (MS; also designed as granulocytic sarcoma or chloroma) is a rare extramedullary tumor composed of immature myeloid cells at different stages of differentiation which can involve any site of the body. Most of MS will develop within the first year preceding the occurrence of acute myeloid leukemia (AML), or concomitantly to AML or at relapse of AML. More rarely, MS could be also observed in the setting of myelodysplastic syndrome or myeloproliferative neoplasms or as an isolated MS (also designated as de novo, non-leukemic or primary MS). 1 Overall results and comparison of outcomes between isolated and leukemic MS are given in Table 2 . Some patients in the leukemic group had received a second allo-transplant in the leukemic group, and could achieve a second persistent CR as reported before. 13 As outcomes of isolated and leukemic MS were found similar, we have pooled the two groups to perform univariate and multivariate analyses. Thus, considering the whole cohort (n=99), in univariate analysis, factors associated with higher LFS and lower RI were CR status at transplant (5- This study included the largest series of isolated MS patients having undergone allo-HSCT, reported thus far. With a 5-years OS and LFS of 48% and 36% respectively, this study suggests that allo-HSCT is a potentially efficient treatment for isolated MS with relatively acceptable toxicity (overall 5-years NRM: 17%). When comparing isolated and leukemic MS, there were no significant differences in term of outcomes. The multivariate analysis showed that CR status at transplant was associated with improved LFS while high risk cytogenetics decreased the chance of long term LFS. If the former result is expected, the latter should be taken with caution, as cytogenetics data was missing in most cases of isolated MS.
We think our results support the use of allo-HSCT as first line therapy for MS, especially in patients achieving CR after AML-type therapy, since one should bear in mind that the prognosis of MS is generally poor with an OS usually less than 2 years in patients not receiving allo-HSCT. 4, 5, 6 The latter is in line with recent guidelines from Dohner et al., 2 recommending the use of AML-like induction therapy for MS, followed by consolidation before proceeding to allo-HSCT. Also, involved field radiation therapy may be considered to enhance local tumor.
Besides cytogenetics, the role of new molecular prognostic markers such as NPM1 or FLT3-ITD mutations in MS should be also investigated as they will likely influence outcome after chemotherapy and/or allo-HSCT. 9 Interestingly, a case report regarding one patient with FLT3-ITD positive MS suggested a beneficial effect of the kinase inhibitor sorafenib.
10
In all, we conclude that allo-HSCT is an effective treatment for patients with MS. Patients with isolated or leukemic MS have similar outcomes after allo-HSCT. While prospective evaluations are needed, allo-HSCT could be presently considered as the optimal therapy for both isolated and leukemic MS. Leukemic MS: skin n=7; soft tissue n=3; bone n=3; testis/ovary n=2; digestive tract n=3; eyes n=2; kidney n=1; oral cavity n=1; lymph nodes n=1; epidural n=1. e Isolated MS: skin and oral cavity n=1; testis/ovary and pleural n=1; heart, pleural and mediastinum n=1; lymph nodes and mediastinum n=1; lymph nodes , digestive tract and bone n=1; bone and jaw n=1; eyes, bone and kidney n=1. Leukemic MS: liver and lymph nodes n=1; skin and soft tissue n=2; skin and sinus n=1; skin and oral cavity n=1, lymph nodes, soft tissue and heart n=1; breast and eyes n=1; breast and kidney n=1. GVHD: graft-versus-host disease; CI: cumulative incidence; OS: overall survival; LFS: leukaemia free survival; CR: complete remission; NRM: non relapse mortality, AML: acute myeloid leukemia; RIC: reduced intensity conditioning; MS: myeloid sarcoma. * P value: comparison between isolated and leukemic myeloid sarcoma patients. **: Considering patients with relapse as MS or MS+AML (n=16), 6 MS relapses occurred at the original site while 10 occurred at a different site.
